Primary Prevention of Cardiovascular Disease in People With Dysglycemia

被引:36
作者
Bianchi, Cristina [1 ]
Miccoli, Roberto [1 ]
Penno, Giuseppe [1 ]
Del Prato, Stefano [1 ]
机构
[1] Univ Pisa, Sect Diabet & Metab Dis, Dept Endocrinol & Metab, Pisa, Italy
关键词
D O I
10.2337/dc08-s256
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease accounts for a great majority of deaths in patients with type 2 diabetes. According to the World Health Organization, the prevalence of cardiovascular disease in diabetic patients ranges from 26 to 36%. Fatality rate after myocardial infarction is greater in diabetic patients, and overall prognosis after coronary heart disease is worse. Based on these observations, it has been proposed that diabetes should be considered as a coronary heart disease risk equivalent. if that is the case, prevention of diabetes and early, intervention should be pursued. This view is supported by the notion that cardiovascular risk is already increased in people with impaired glucose tolerance. Moreover, higher-than-optimum blood glucose is a major cause of cardiovascular mortality in most world regions Of the world. Whether dysglycemia is a marker for a more complex Metabolic condition or may directly contribute to excess cardiovascular risk is still a matter of debate, However, experimental work has shown how increased glucose level can trigger multiple mechanisms of susceptibility to atherosclerosis, and diabetes prevention trials have indicated that along with reduction of the rate of conversion toward diabetes, significant improvement in cardiovascular risk factors occurs. Moreover, in the STOP-NIDDM trial, targeting postprandial glucose was associated With reduction in new cases of hypertension, myocardial infarction, and any cardiovascular events. In conclusion, dysglycemia should be included in the list of established cardiovascular risk factors and early treatment introduced in the attempt to improve cardiovascular morbidity and mortality.
引用
收藏
页码:S208 / S214
页数:7
相关论文
共 62 条
[11]   Impaired glucose tolerance and cardiovascular disease: The possible role of post-prandial hyperglycemia [J].
Ceriello, A .
AMERICAN HEART JOURNAL, 2004, 147 (05) :803-807
[12]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[13]   The relationship between glucose and incident cardiovascular events [J].
Coutinho, M ;
Gerstein, HC ;
Wang, Y ;
Yusuf, S .
DIABETES CARE, 1999, 22 (02) :233-240
[14]   Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment [J].
Danaei, Goodarz ;
Lawes, Carlene M. M. ;
Hoorn, Stephen Vander ;
Murray, Christopher J. L. ;
Ezzati, Majid .
LANCET, 2006, 368 (9548) :1651-1659
[15]   Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population:: the Hoorn Study [J].
de Vegt, F ;
Dekker, JM ;
Ruhé, HG ;
Stehouwer, CDA ;
Nijpels, G ;
Bouter, LM ;
Heine, RJ .
DIABETOLOGIA, 1999, 42 (08) :926-931
[16]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[17]   In search of normoglycaemia in diabetes: controlling postprandial glucose [J].
Del Prato, S .
INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 (Suppl 3) :S9-S17
[18]   Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia [J].
Despres, JP ;
Golay, A ;
Sjostrom, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2121-2134
[19]  
Diabet Prevention Program Res Grp, 2005, DIABETES, V54, P1566
[20]   Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome - A summary of the evidence [J].
Ford, ES .
DIABETES CARE, 2005, 28 (07) :1769-1778